Money-back guarantees on cancer drugs are real in Italy, and the world is watching

Tracy Staton One country is ahead of the curve in striking pay-for-performance deals on cancer drugs–and, more importantly, collecting the cash when treatments don't hit their ...

Biden maps out a ‘moonshot’ approach to cancer with plans to ‘break down silos’ in R&D

Damian Garde Vice President Joe Biden fleshed out his plans to take the lead on a global effort to bolster cancer research, hoping to unite industry and academia to push new therapies ...

Roche and AbbVie line up for quick approval for cancer drug venetoclax

Damian Garde Partners Roche and AbbVie are speeding toward FDA approval with a cancer treatment tabbed as a potential blockbuster, picking up a priority review for a blood cancer therapy. FierceBiotech ...

Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma

John Carroll Less than a year after Sanofi downsized its cancer drug R&D operations, the pharma giant has struck back-to-back deals to launch new immuno-oncology drug programs, ...

GlaxoSmithKline and Five Prime ditch lung cancer ambitions as rivals pile in

Damian Garde Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape ...

Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to ...

Discount sways U.K. cost gatekeeper on AstraZeneca’s ovarian cancer med Lynparza

Emily Wasserman AstraZeneca scored a victory for its ovarian cancer drug Lynparza, as U.K. cost watchdog the National Institute for Health and Care Excellence did an about-face and ...

Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration

Damian Garde Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. FierceBiotech ...

Pfizer nabs speedy FDA review for new use of lung cancer med Xalkori

Carly Helfand Pfizer's Xalkori is already used to treat patients with metastatic non-small cell lung cancer whose tumors are ALK-positive. But now it's on its way to snagging ...

Startup raises $15M to turn an old diabetes drug into a potent cancer killer

Damian Garde A group of scientists at UCLA have cooked up some compounds that could harness the cancer-fighting properties of metformin while avoiding the biological hurdles that have ...

Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti

Carly Helfand After winning FDA approval Monday, the latest multiple myeloma treatment–Empliciti, from Bristol-Myers Squibb and AbbVie–is about to hit the scene. And like ...

Lilly’s middling lung cancer drug wins FDA approval with a restrictive label

Damian Garde Eli Lilly won FDA approval for a lung cancer treatment that posted only a marginal survival benefit in late-stage clinical trials, gaining clearance to treat a small population ...
Page 2 of 2312345...1020...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS